SCHEMBL2225236

SCHEMBL2225236

NS(=O)(=O)c1ccc(N2CCOCC2)c(CNc2cc(Nc3ccc(Cl)cc3)ncn2)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TNNI3K Q59H18 4/20 0.51
EGFR P00533 2/20 0.50
CA12 O43570 3/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA9 Q16790 3/20 0.47
JAK2 O60674 7/20 0.47
JAK1 P23458 5/20 0.47
JAK3 P52333 6/20 0.46
TYK2 P29597 1/20 0.46
CDK1 P06493 1/20 0.45
CCNB1 P14635 1/20 0.45
CCNA2 P20248 1/20 0.45
CCNE1 P24864 1/20 0.45
CDK2 P24941 1/20 0.45
CDK5 Q00535 1/20 0.45
CDK5R1 Q15078 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2227348 0.85 JAK2 (0.45) EGFRCA12CA1CA2CA9
SCHEMBL2226690 0.79 TNNI3K (0.64) TNNI3KCDK1CCNB1CCNA2CCNE1
SCHEMBL2227374 0.78 CDK1 (0.51) TNNI3KEGFRCDK1CCNB1CCNA2
SCHEMBL2227638 0.78 TNNI3K (0.57) TNNI3KEGFRCA12CA1CA2
SCHEMBL2227311 0.78 TNNI3K (0.61) TNNI3KEGFRCA1CA2CA9
SCHEMBL2227068 0.76 CDK1 (0.48) TNNI3KEGFRCDK1CCNB1CCNA2
SCHEMBL2225574 0.75 TNNI3K (0.59) TNNI3KEGFRCDK1CCNB1CCNA2
SCHEMBL12517487 0.75 TNNI3K (0.84) TNNI3K
SCHEMBL2226058 0.75 TNNI3K (0.49) TNNI3KEGFRCDK1CCNB1CCNA2
SCHEMBL2226278 0.75 TNNI3K (0.52) TNNI3KEGFRCDK1CCNB1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523559-A1 COMPOUNDS AND METHODS GlaxoSmithKline LLC (US) 2012-11-21 EP claimed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO claimed
EP-2523559-A1 COMPOUNDS AND METHODS GlaxoSmithKline LLC (US) 2012-11-21 EP disclosed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO disclosed